Brevan Howard Capital Management’s Summit Therapeutics SMMT Stock Holding History

Brevan Howard Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$658K	Buy	+45,164	New	+$801K	﹤0.01%	1299
2025 Q4	–	Sell	-11,351	Closed	-$235K	–	2242
2025 Q3	$235K	Sell	11,351 -93,309	-89%	-$2.26M	﹤0.01%	1683
2025 Q2	$2.23M	Buy	+104,660	New	+$2.39M	0.01%	692
2024 Q3	–	Sell	-31,214	Closed	-$243K	–	1414
2024 Q2	$243K	Buy	+31,214	New	+$169K	﹤0.01%	834

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Brevan Howard Capital Management's SMMT Position: Q2 2026 in Review

Brevan Howard Capital Management opened a new position in Summit Therapeutics (SMMT) in Q2 2026: 45,164 shares worth $658K. The stake represents ﹤0.01% of the portfolio and ranks #1299 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in SMMT as recently as Q3 2025.

Brevan Howard Capital Management first reported a position in SMMT in Q2 2024 and has held it in 4 quarters since. The position peaked at $2.23M in Q2 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Brevan Howard Capital Management held 45,164 shares of Summit Therapeutics worth $658K as of Q2 2026.
Summit Therapeutics was a new Brevan Howard Capital Management position in Q2 2026.
Summit Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1299 holding.
Brevan Howard Capital Management first reported a position in Summit Therapeutics in Q2 2024 and has held it in 4 quarters since.
Brevan Howard Capital Management's Summit Therapeutics position peaked at $2.23M in Q2 2025.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.